July 25, 2016
Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies
Platform for Renewable T-Cell Source Designed to Overcome Limitations of Current Allogeneic Approaches
The technology is based on research led by
Pluripotent stem cells have the potential to develop into many different cell types, including T-cells. T-cell development is complex, and attempts to generate T-cells with in vitro cell culture systems have been limited by low output of T-cells and donor-to-donor variability that cannot support further engineering or commercial-scale manufacturing. In contrast, the ATO system potentially supports efficient and scalable production of T-cells using pluripotent stem cell lines capable of indefinite self-renewal. With reproducible and consistent production of T-cells, the ATO system presents an attractive platform to facilitate additional gene-engineering steps to develop off-the-shelf allogeneic T-cell therapies.
"This ATO system represents a significant breakthrough in stem cell biology that will drive our long-term strategy to develop best-in-class allogeneic T-cell therapies," said
Under the terms of this agreement, Kite will receive exclusive rights to use the licensed technology to develop and commercialize T-cell products in oncology. In connection with the license agreement, Kite has entered into a Sponsored Research Agreement with
About the ATO System
The artificial thymic organoid (ATO) system is an in vitro model that artificially mimics the thymic environment to recapitulate human T-cell development. The ATO system supports efficient differentiation and positive selection of normal T-cells using hematopoietic stem cells from various sources, as well as pluripotent stem cells, like embryonic stem cells and induced pluripotent stem cells. The technology also offers flexibility for further gene engineering to produce off-the-shelf allogeneic engineered T-cell products for therapeutic use.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success of the ATO system and the ability to develop allogeneic product candidates and the ability to control the activity of such product candidates; and the ability to advance Kite's pipeline through new technologies. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the
News Provided by Acquire Media